Literature DB >> 6325205

Comparison of changes in the characteristics of beta-adrenoceptors and responsiveness of human circulating lymphocytes during and after chronic administration of pindolol and propranolol.

Y Giudicelli, D Lacasa, B Agli, A Leneveu.   

Abstract

The characteristics of the beta-adrenoceptors (3H-dihydroalprenolol binding) and the beta-adrenergic responsiveness (cyclic AMP response to isoproterenol) were studied in circulating lymphocytes from healthy volunteers before (D 0), on the 22nd day of treatment (D 22) and on the fifth day (D 30) following discontinuation of pindolol 15 mg/day or propranolol 160 mg/day. During pindolol therapy (D 22) the beta-adrenoceptor-affinity towards dihydroalprenolol was unchanged and the beta-adrenoceptor density decreased by 50%, an effect which persisted after drug administration ceased (D 30). The receptor "down-regulation" was accompanied by a parallel decrease in the maximal lymphocyte response to isoproterenol on D 22 and 30, by a shift to the right of the concentration-response curves to isoproterenol on D 22 and 30. In contrast, no significant modification in beta-adrenoceptor density or in the maximal response to isoproterenol was observed during (D 22) or after discontinuation (D 30) or propranolol therapy; the beta-adrenoceptor affinity for dihydroalprenolol and the sensitivity of the lymphocyte response to isoproterenol were markedly reduced on D 22 but not on D 30. It is concluded that the lymphocyte beta-adrenoceptor "down regulation" and the parallel beta-adrenergic desensitization induced by chronic pindolol therapy are both due to the intrinsic sympathomimetic activity of this drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325205     DOI: 10.1007/bf00546700

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  beta-Adrenergic receptor desensitization in rat adipocyte membranes.

Authors:  Y Giudicelli; B Agli; D Lacasa
Journal:  Biochim Biophys Acta       Date:  1979-06-01

2.  Role of beta-adrenergic receptors in catecholamine-induced desensitization of adenylate cyclase in human astrocytoma cells.

Authors:  G L Johnson; B B Wolfe; T K Harden; P B Molinoff; J P Perkins
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

5.  Beta-blocker withdrawal syndrome.

Authors:  O Lederballe Pedersen; E Mikkelsen
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

Review 6.  Effects of drugs on beta-adrenergic receptors on human lymphocytes.

Authors:  P B Molinoff; R D Aarons
Journal:  J Cardiovasc Pharmacol       Date:  1983       Impact factor: 3.105

7.  Characteristics of beta-adrenergic-agonist binding to rat adipocyte membranes. Evidence that (+/-)-[3H]hydroxybenzylisoproterenol interacts selectively with the adipocyte beta-adrenergic receptors.

Authors:  Y Giudicelli; D Lacasa; B Agli
Journal:  Biochim Biophys Acta       Date:  1982-03-15

8.  Changes in the density of beta adrenergic receptors in rat lymphocytes, heart and lung after chronic treatment with propranolol.

Authors:  R D Aarons; P B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

9.  Mechanism of propranolol withdrawal phenomena.

Authors:  S Nattel; R E Rangno; G Van Loon
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

10.  Regulation of lipolysis and cyclic AMP synthesis through energy supply in isolated human fat cells.

Authors:  Y Giudicelli; R Pecquery; D Provin; B Agli; R Nordmann
Journal:  Biochim Biophys Acta       Date:  1977-02-23
View more
  8 in total

1.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Selective regulation of beta 1- and beta 2-adrenoceptors in the human heart by chronic beta-adrenoceptor antagonist treatment.

Authors:  M C Michel; A Pingsmann; J J Beckeringh; H R Zerkowski; N Doetsch; O E Brodde
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

3.  Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism.

Authors:  K Whyte; C R Jones; C A Howie; N Deighton; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 4.  Beta receptor antagonists in the treatment of heart failure.

Authors:  H Persson; L Erhardt
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

5.  Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study.

Authors:  Heike Bruck; Ulrike Poller; Hendrik Lüssenhop; Klaus Pönicke; Thomas Temme; Gerd Heusch; Thomas Philipp; Otto-Erich Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

6.  Adimolol, a long acting beta-adrenoceptor blocker in man.

Authors:  H L Elliott; C R Jones; N M Deighton; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

7.  Effects of beta-adrenoceptor antagonist administration on beta 2-adrenoceptor density in human lymphocytes. The role of the "intrinsic sympathomimetic activity".

Authors:  O E Brodde; A Daul; N Stuka; N O'Hara; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

8.  Beta-adrenoceptor antagonists (non-selective as well as beta 1-selective) with partial agonistic activity decrease beta 2-adrenoceptor density in human lymphocytes. Evidence for a beta 2-agonistic component of the partial agonistic activity.

Authors:  O E Brodde; R Schemuth; M Brinkmann; X L Wang; A Daul; U Borchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-06       Impact factor: 3.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.